Reversal of new oral anticoagulants.

نویسنده

  • Elisabeth M Battinelli
چکیده

Although the options for therapeutic modalities such as chemotherapy and antibiotics have flourished, anticoagulant management has remained stagnant since the first agents were developed during World War II. Traditional anticoagulants widely used to treat thromboembolic disease include heparin-based drugs and warfarin. These drugs are cumbersome to administer. They have a narrow therapeutic window to achieve adequate anticoagulation without bleeding, and they exhibit interactions with food and other drugs that led to the requirement for frequent monitoring by laboratory testing. Until recently, few other options remained for antithrombotic therapy. Recently, however, there has been an influx of new anticoagulants poised to enter the market, providing more therapeutic options for patients. They promise to be better than current agents because they achieve similar, if not better, efficacy with less bleeding and fewer interactions with food and drugs and without the need for frequent monitoring.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report

With the arrival of a new generation of oral anticoagulants significant burdens associated with warfarin's use on both the patient and the healthcare system have been alleviated. Nevertheless, a shortfall exists in regard to an agent or protocol for reversal of these new anticoagulants in the setting of an acute bleed. Our case of a patient presenting to the hospital with a vaginal bleed while ...

متن کامل

Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications

New oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, have been recently approved for primary and secondary prophylaxis of thromboembolic conditions. However, there is no clear strategy for managing and reversing their anticoagulant effects. We aimed to summarize the available evidence for clinical management and reversal of bleeding associated with new oral anticoagulants. ...

متن کامل

An Overview of Novel Anticoagulants

Arterial and venous thromboembolism is one of the most common causes of death worldwide. For almost seventy years, heparin, low molecular weight heparin, and vitamin K antagonists have been widely used in the prevention and treatment of thromboembolic disorders. However, many of the limitations of these traditional anticoagulants have led to the search for and attempts to introduce better drug ...

متن کامل

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Newer oral anticoagulants offer several advantages over traditional agents (e.g. warfarin), but they are still associated with a bleeding risk and currently there is no validated reversal treatment for them. While there is little support for the use of fresh frozen plasma, and limited data available on the effects of activated recombinant factor VII, preclinical data suggest that prothrombin co...

متن کامل

The role of prothrombin complex concentrates in reversal of target specific anticoagulants

Over the past several years a new era for patients requiring anticoagulation has arrived. The approval of new target specific oral anticoagulants offers practitioners several advantages over traditionally used vitamin K antagonist agents including predictable pharmacokinetics, rapid onset of action, comparable efficacy and safety, all without the need for routine monitoring. Despite these benef...

متن کامل

Managing patients taking edoxaban in dentistry

BACKGROUND Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. A new group of oral anticoagulants with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years. The Food and Drug Administration has approved edoxaban, dabigatran, rivaroxaban and apixaban. Their advantages include: predictab...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Circulation

دوره 124 14  شماره 

صفحات  -

تاریخ انتشار 2011